Finished Studies

A Study of the Prevalence of Apolipoprotein L1 (APOL1) Alleles Among Individuals With Proteinuric Kidney Disease Who Are of Recent African Ancestry or Geographic Origin (Sponsor: Vertex Pharmaceuticals)

Phase 3

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy & Safety of SNF472 When Added to Background Care for Treatment of Calciphylaxis (Sponsor: Sanifit Therapeutics)

Phase 2

A Multicenter, Double blind, Randomized, Placebo Controlled parallel group, phase 2 study to evaluate the efficacy and safety of LNP023 in primary IgA nephropathy patients (Sponsor: Novartis)

Transition of Renal Patients using Allosure into Community Kidney Care – TRACK (Sponsor: CareDx)

Application of Cell-free DNA in Kidney Transplant Patients in the Local Community Nephrology Clinics - IIT (Sponsor: CareDx)

Phase 3

A Phase III Randomized, Double-blind, Placebo-controlled, Multi-center Study in Adults to Determine the Safety and Efficacy of AZD7442, a Combination Product of Two Monoclonal Antibodies (AZD8895 and AZD1061), for Post-Exposure Prophylaxis of COVID-19. (Sponsor: AstraZeneca)

A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion from a Long-acting Erythropoiesis-stimulating agent (MIRCERA) to Three Times Weekly Oral VADUSTAT for the Maintenance Treatment of Anemia in Hemodialysis Subjects (Sponsor: Akebia)

Role of Intermittent Pneumatic Compression Device in increasing vein diameter in Patients with Kidney Disease requiring Arteriovenous Fistulas (Sponsor: FistAssist)

A Multicenter, Randomized, Double-blind, Active-controlled Study to Evaluate the Effects of LCZ696 Compared to Valsartan on Cognitive Function in Patients with Chronic Heart Failure and Preserved Ejection Fraction (Sponsor: Novartis)

Multi-center Cross-sectional Epidemiological Study to Characterize the Prevalence and Distribution of Lipoprotein(a) Levels Among Patients with Established Cardiovascular Disease (Sponsor: Novartis)

Phase 2

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of GalNAc-conjugated FXI Antisense Oligonucleotide in Patients with End-Stage Renal Disease on Hemodialysis (Sponsor: Bayer)

A 28-week, randomized, double-blind, placebo-controlled, parallel group, multi-center, study in recombinant human erythropoietin (rhEPO) naïve non-dialysis participants with anemia associated with chronic kidney disease to evaluate the efficacy, safety, and effects on quality of life of Daprodustat compared to placebo (Sponsor: GlaxoSmithKline)

Phase 3

A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal, Parallel Group Study of Patiromer for the Management of Hyperkalemia in Subjects Receiving Renin-Angiotensin-Aldosterone System Inhibitor (RAASi) Medications for the Treatment of Heart Failure (DIAMOND) (Sponsor: Relypsa)